BrightFocus-Funded Research Shows Parkinson’s Drug Could be Repurposed to Save Sight of Millions
In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.
The findings, published in the American Journal of Medicine, are a groundbreaking effort in the fight against age-related macular degeneration (AMD), which affects as many as 11 million Americans. AMD hinders central vision, and even when it does not lead to blindness it can severely reduce the ability to read, drive, and recognize faces.
In the study, supported in part by BrightFocus Foundation, researchers discovered a biological connection between darker pigmented eyes, that are known to be resistant to AMD, and increased levels of a chemical called L-DOPA in those eyes. Since L-DOPA is frequently prescribed for Parkinson’s patients, the researchers wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. By combing through massive databases of medical chart data, they reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
“Rather than looking at what might cause AMD, we instead wondered why certain people are protected from AMD. This approach had never been done before,” says senior author Brian McKay of the University of Arizona.
The research findings are based off an analysis of the medical records of 37,000 patients at the Marshfield Clinic in Wisconsin. Because the average age of those given L-DOPA is 67, while the average age of AMD diagnosis is 71, scientists were able to effectively track patterns. These major findings were then confirmed by reviewing a data set of 87 million patients. In this large scale data set, L-DOPA also delayed or prevented AMD from progressing to its “wet” form, the most devastating form of the disease.
“This exciting breakthrough shows the power of scientific discovery to give hope to millions of people across the nation and the world. Their methodology is a reminder that ‘big data’ is not a buzzword—it is a bold and innovative new approach to science,” said BrightFocus president and CEO Stacy Pagos Haller.
The Latest on: L-DOPA
via Google News
The Latest on: L-DOPA
- Neuropathy in Parkinson’s Disease May Be Related to L-Dopa Exposureon July 20, 2019 at 5:00 pm
Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ... […]
- Infographic: Gut Microbes Change How Well Drugs Workon July 14, 2019 at 9:12 pm
One example is the Parkinson’s drug levodopa (L-dopa), for which studies have suggested these interactions help explain differences in efficacy among individuals. After crossing the blood-brain ... […]
- Gut-Dwelling Bacterium Consumes Parkinson’s Drugon June 25, 2019 at 9:33 am
There have been previous hints that gut microbes might influence the effectiveness of levodopa (L-dopa), which helps to ease the stiffness, rigidity, and slowness of movement associated with Parkinson ... […]
- Gut Bacteria May Be Eating Our Medication And Making It Ineffective, Study Suggestson June 18, 2019 at 8:52 am
One of those drugs is L-dopa, a treatment for the neurological condition Parkinson's, which causes patients to experience tremors, muscle rigidity, and difficulty balancing. More than 1 percent of ... […]
- Eyeing personalized Rx, Harvard, UCSF uncover L-dopa microbial metabolismon June 17, 2019 at 5:00 pm
There is wide variability of individual responses to a specific prescription drug. That can have some genetic basis inherent to a particular individual, but the microbiome also has been suspected to ... […]
- Rigorous study explains how a single gut bacteria species can eat Parkinson’s disease drugon June 13, 2019 at 9:09 pm
For decades Levodopa (L-dopa) has been the only effective drug treatment for Parkinson's disease sufferers. However, the efficacy of the drug is known to vary dramatically from patient to patient. ... […]
- Gut microbes eat our medicationon June 13, 2019 at 12:39 pm
Focusing on levodopa (L-dopa), the primary treatment for Parkinson's disease, they identified which bacteria out of the trillions of species is responsible for degrading the drug and how to stop this ... […]
- L-Dopa in Parkinson's Syndromeon June 5, 2019 at 5:00 pm
Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services. The authorized source of trusted medical ... […]
- Polyphenolic Substance of Mytilus edulis: Novel Adhesive Containing L-Dopa and Hydroxyprolineon June 3, 2019 at 5:33 pm
The fouling marine mussel Mytilus edulis attaches itself to various substrates by spinning byssal threads, the adhesive discs of which are rich in the amino acid 3,4-dihydroxyphenylalanine (dopa). An ... […]
- Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesiaon March 3, 2019 at 4:00 pm
1 Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 171 77 Stockholm, Sweden. 2 Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA. ... […]
via Bing News